149 related articles for article (PubMed ID: 25788219)
41. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
[TBL] [Abstract][Full Text] [Related]
42. miR-106b promotes cancer progression in hepatitis B virus-associated hepatocellular carcinoma.
Yen CS; Su ZR; Lee YP; Liu IT; Yen CJ
World J Gastroenterol; 2016 Jun; 22(22):5183-92. PubMed ID: 27298561
[TBL] [Abstract][Full Text] [Related]
43. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
44. Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C.
Fukushima N; Kuromatsu R; Arinaga-Hino T; Ando E; Takata A; Sumie S; Nakano M; Kawaguchi T; Ide T; Torimura T; Sata M
Hepatol Res; 2010 Sep; 40(9):911-22. PubMed ID: 20887596
[TBL] [Abstract][Full Text] [Related]
45. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
46. Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis.
Manthravadi S; Paleti S; Pandya P
Int J Cancer; 2017 Mar; 140(5):1042-1049. PubMed ID: 27861842
[TBL] [Abstract][Full Text] [Related]
47. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.
Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Roudot-Thoraval F; Audureau E;
Gastroenterology; 2018 Nov; 155(5):1436-1450.e6. PubMed ID: 30031138
[TBL] [Abstract][Full Text] [Related]
48. Molecular Mechanisms of Hepatocarcinogenesis Following Sustained Virological Response in Patients with Chronic Hepatitis C Virus Infection.
Hayes CN; Zhang P; Zhang Y; Chayama K
Viruses; 2018 Sep; 10(10):. PubMed ID: 30274202
[TBL] [Abstract][Full Text] [Related]
49. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
[TBL] [Abstract][Full Text] [Related]
50. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
51. Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals.
Syed T; Fazili J; Ali IA; Zhao D; Hughes D; Mahmood S
Cureus; 2018 Jun; 10(6):e2843. PubMed ID: 30280052
[TBL] [Abstract][Full Text] [Related]
52. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Chen TM; Lin CC; Huang PT; Wen CF
Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
[TBL] [Abstract][Full Text] [Related]
53. Transcriptomic Analysis of Chronic Hepatitis B and C and Liver Cancer Reveals MicroRNA-Mediated Control of Cholesterol Synthesis Programs.
Selitsky SR; Dinh TA; Toth CL; Kurtz CL; Honda M; Struck BR; Kaneko S; Vickers KC; Lemon SM; Sethupathy P
mBio; 2015 Dec; 6(6):e01500-15. PubMed ID: 26646011
[TBL] [Abstract][Full Text] [Related]
54. Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.
Ogasawara N; Saitoh S; Akuta N; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
Hepatol Res; 2019 Dec; 49(12):1441-1450. PubMed ID: 31373093
[TBL] [Abstract][Full Text] [Related]
55. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.
Zekri AN; Youssef AS; El-Desouky ED; Ahmed OS; Lotfy MM; Nassar AA; Bahnassey AA
Tumour Biol; 2016 Sep; 37(9):12273-12286. PubMed ID: 27271989
[TBL] [Abstract][Full Text] [Related]
56. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response.
Sasaki R; Kanda T; Kato N; Yokosuka O; Moriyama M
World J Hepatol; 2018 Dec; 10(12):898-906. PubMed ID: 30631394
[TBL] [Abstract][Full Text] [Related]
58. [Recent Advances in Anti-Hepatitis C Viral Treatment and Future Perspective].
Asahina Y
Rinsho Byori; 2016 Jul; 64(7):780-786. PubMed ID: 30695466
[TBL] [Abstract][Full Text] [Related]
59. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
60. Characteristics and Prognosis of
Toyoda H; Hiraoka A; Uojima H; Nozaki A; Shimada N; Takaguchi K; Abe H; Atsukawa M; Matsuura K; Ishikawa T; Mikami S; Watanabe T; Itobayashi E; Tsuji K; Arai T; Yasuda S; Chuma M; Senoh T; Tsutsui A; Okubo T; Ehira T; Kumada T; Tanaka J
Hepatol Commun; 2021 Jul; 5(7):1290-1299. PubMed ID: 34278176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
